Analyst Price Target News: Amphastar, Lantronix – May 12th, 2025

By: Matthew Otto

Blend Reports Q1 2025 Operational Metrics Despite Revenue Miss and Lower EPS

Blend Labs reported its third consecutive quarter of year-over-year growth. Platform revenue for the first quarter reached $26.8 million, which is below the consensus estimate of $43.2 million. Blend Labs posted an earnings per share (EPS) loss of $0.01, underperforming analyst expectations by $0.02.

Software platform revenue grew 12% year-over-year to $24.3 million, led by a 45% increase in Consumer Banking Suite revenue to $9.6 million, partially offset by a 3% decline in Mortgage Suite revenue to $14.6 million.

Blend also recorded its first quarter of positive free cash flow at $15.5 million, with $20.1 million in cash provided by operating activities. Remaining performance obligations surged 70% year-over-year to $158.1 million.

Operating losses narrowed to $7.7 million from $21.2 million a year ago, while adjusted operating income turned positive at $1 million. For the second quarter, Blend expects platform revenue between $30.5 million and $32.5 million and full-year operating expenses of $85 million to $90 million.

Analyst Reaffirms Rating Following Q1 Metrics and Software Momentum

Canaccord Genuity analyst Joseph Vafi maintained a Buy rating and a $5.25 price target.

Which Analyst has the best track record to show on BLND?

Analyst Michael Turrin (WELLS FARGO) currently has the highest performing score on BLND with 8/13 (61.54%) price target fulfillment ratio. His price targets carry an average of $1.89 (60.77%) potential upside. Blend Labs stock price reaches these price targets on average within 79 days.

Amphastar Tops Earnings Estimates Despite Revenue Miss and Decline in Profitability

Amphastar Pharmaceuticals reported net revenues of $170.5 million for the first quarter ended March 31, 2025. This is below the consensus estimate of $174.35 million and down 1% from $171.8 million in the same period last year.

Earnings per share came in at $0.74, exceeding analyst expectations by $0.05. Net income was $25.3 million, or $0.51 per share, compared to $43.2 million, or $0.81 per share, a year ago. Gross profit was $85.3 million with a margin of 50%, down from 52.4% last year, impacted by pricing pressure on epinephrine and higher labor costs. Operating cash flow totaled $35.1 million. Adjusted net income for the quarter was $36.9 million, compared to $55.3 million in Q1 2024.

BAQSIMI® led Amphastar’s product growth, generating $38.4 million in sales—a 177% year-over-year increase—following the assumption of global distribution. BAQSIMI® is designed to treat severe hypoglycemia—an acute and potentially life-threatening drop in blood glucose levels—in people with diabetes. According to the Centers for Disease Control and Prevention (CDC), over 37 million Americans have diabetes, and roughly 7 million of them use insulin, putting them at direct risk for severe hypoglycemic events.

Clinical studies and real-world data suggest that among insulin users, 20% to 40% may experience at least one severe hypoglycemic episode annually. That translates to approximately 1.4 to 2.8 million people in the U.S. each year who could potentially benefit from an emergency rescue treatment like BAQSIMI®.

Product revenues rose 8% year-over-year, though overall net revenues decreased due to the absence of $14.2 million in transitional revenue from BAQSIMI® recorded in Q1 2024. Selling, distribution, and marketing expenses increased 27%, while R&D expenses rose 18% to $20.1 million, driven by expanded clinical activities and FDA filing costs. Amphastar’s pipeline includes multiple biosimilar and proprietary candidates targeting market segments worth over $10 billion in aggregate.

Analyst Adjusts Price Target Amid Revenue Miss and Margin Pressure

JP Morgan analyst Ekaterina Knyazkova downgraded from Overweight to Neutral and lowered the price target from $45 to $30.

Which Analyst has the best track record to show on AMPH?

Analyst David Amsellem (PIPER SANDLER) currently has the highest performing score on AMPH with 10/15 (66.67%) price target fulfillment ratio. His price targets carry an average of $3.71 (13.11%) potential upside. Amphastar Pharmaceuticals stock price reaches these price targets on average within 337 days.

Lantronix Reports Third Quarter FY2025 Results and Provides Fourth Quarter Outlook

Lantronix reported third-quarter fiscal 2025 earnings of $0.03 per share, which was $0.05 below the analyst estimate of $0.08. Revenue for the quarter was $28.5 million, falling short of the consensus estimate of $34.09 million. This represents a slight decrease from the $28.6 million reported in Q3 FY2024.

For the fourth quarter of fiscal 2025, Lantronix expects earnings to be between $0.00 and $0.02 per share, compared to the consensus estimate of $0.03. Lantronix forecasts Q4 revenue in the range of $26.5 million to $30.5 million, missing the consensus estimate of $30.12 million.

Analysts Maintain Ratings, Adjust Price Targets After Q3 Results

Canaccord Genuity analyst George Gianarikas maintained a Buy rating but lowered the price target from $4.5 to $3.
Needham analyst Ryan Koontz kept a Buy rating but reduced the price target from $5.5 to $4.5.

Which Analyst has the best track record to show on LTRX?

Analyst Jaeson Schmidt (LAKE STREET) currently has the highest performing score on LTRX with 2/7 (28.57%) price target fulfillment ratio. His price targets carry an average of $1.9 (90.48%) potential upside. Lantronix stock price reaches these price targets on average within 612 days.